

25 March 2010

The Manager  
Company Announcements Office  
ASX Limited  
20 Bridge St  
SYDNEY NSW 2000

Dear Sir,

**APPENDIX 3Y**

On 23 March 2010 a CBio Limited shareholder, Australian Technology Innovation Fund Limited, conducted an in-specie distribution of its CBio holding to its members.

Mr Stephen Jones, Dr Michael Monsour and Mr Stephen Streeter are shareholders in Australian Technology Innovation Fund Limited and received CBio shares as part of this in-specie distribution.

Appendix 3Y's in relation to the distribution are attached to this notice.

For and on behalf of the Board



**BEN GRAHAM**  
Company Secretary

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>CBIO LIMITED</b>
<b>ABN</b>	<b>76 094 730 417</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	MR STEPHEN JONES
<b>Date of last notice</b>	17 FEBRUARY 2010

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct – Mr Stephen Jones Indirect- described below
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> <li>1. Stephen George Burch Jones &amp; Nadine Jones &lt;S &amp; N Super Fund A/C&gt;</li> <li>2. Australian Technology Innovation Fund Limited.</li> <li>3. Australian Biofunds Investments Limited</li> <li>4. Emrold Pty Ltd &lt;ATF Jones Family Trust&gt;</li> </ol> <p>Mr Jones is a beneficiary of the S &amp; N Super Fund (at 1 above) and is a Director and shareholder of the entities identified at 2,3&amp;4.</p>
<b>Date of change</b>	23 March 2010

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. Stephen Jones 33 ordinary shares</li> <li>2. Stephen George Burch Jones &amp; Nadine Jones &lt;S &amp; N Super Fund A/C&gt; 1,190,000 ordinary shares and 300,000 share options</li> <li>3. Australian Technology Innovation Fund Limited 3,373,598 ordinary shares</li> <li>4. Australian Biofunds Investments Limited 199,553 ordinary shares</li> <li>5. Emrold Pty Ltd &lt; ATF Jones Family Trust &gt; nil</li> </ol>
<b>Class</b>	Ordinary
<b>Number acquired</b>	Stephen Jones: 6 Emrold Pty Ltd <Jones Family A/C>: 424,520
<b>Number disposed</b>	Australian Technology Innovation Fund Limited: 3,004,843 ordinary shares
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	38 cents per share based on closing share price 23 March 2010.
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. Stephen Jones 39 ordinary shares</li> <li>2. Stephen George Burch Jones &amp; Nadine Jones &lt;S &amp; N Super Fund A/C&gt; 1,190,000 ordinary shares and 300,000 share options</li> <li>3. Australian Technology Innovation Fund Limited 368,755 ordinary shares</li> <li>4. Australian Biofunds Investments Limited 199,553 ordinary shares</li> <li>5. Emrold Pty Ltd &lt; ATF Jones Family Trust &gt; 424,520</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired by Mr Stephen Jones and associated entities were part of an in-specie distribution conducted by Australian Technology Innovation Fund Limited.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
<b>Interest after change</b>	n/a

---

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>CBIO LIMITED</b>
<b>ABN</b>	<b>76 094 730 417</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	MR STEPHEN STREETER
<b>Date of last notice</b>	17 FEBRUARY 2010

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> <li>1. S &amp; M Streeter Investments Co Pty Ltd.</li> <li>2. Australian Technology Innovation Fund Limited.</li> <li>3. Australian Biofund Investments Limited</li> </ol> <p>Mr Streeter is a Director and shareholder of the entities identified above.</p>
<b>Date of change</b>	23 March 2010
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. S &amp; M Streeter Investments Co Pty Ltd: 105,682 ordinary shares &amp; 1,550,000 share options.</li> <li>2. Australian Technology Innovation Fund Limited: 3,373,598 ordinary shares</li> <li>3. Australian Biofund Investments Limited- 199,553 ordinary shares</li> </ol>
<b>Class</b>	Ordinary
<b>Number acquired</b>	S & M Streeter Investments Co Pty Ltd: 150,907 ordinary shares
<b>Number disposed</b>	Australian Technology Innovation Fund Limited: 3,004,843 ordinary shares

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	38 cents per share based on closing share price 23 March 2010.
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. S &amp; M Streeter Investments Co Pty Ltd: 256,589 ordinary shares &amp; 1,550,000 share options.</li> <li>2. Australian Technology Innovation Fund Limited: 368,755 ordinary shares</li> <li>3. Australian Biofund Investments Limited: 199,553 ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired by S & M Streeter Investments Co Pty Ltd were part of an in-specie distribution conducted by Australian Technology Innovation Fund Limited.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>CBIO LIMITED</b>
<b>ABN</b>	<b>76 094 730 417</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	DR MICHAEL MONSOUR
<b>Date of last notice</b>	17 FEBRUARY 2010

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct: Dr Michael Monsour Indirect: Described below
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> <li>1. MP Monsour Medical Practice Pty Ltd &lt;MP Monsour Medical Practice Superannuation Fund A/C&gt;</li> <li>2. MPAMM Pty Ltd</li> <li>3. Australian Technology Innovation Fund Limited.</li> <li>4. Australian Biofunds Investments Limited</li> </ol> <p>Dr Monsour is a Director and shareholder of the entities identified above.</p> <ol style="list-style-type: none"> <li>5. Dr Michael Monsour &lt;Spyder Foundation A/C&gt;</li> </ol> <p>Due to an administrative error, Dr Monsour is currently the registered holder of the Spyder Foundation holding in CBio. This error is currently being rectified by Dr Monsour and will result in a further Appendix 3Y in due course.</p>
<b>Date of change</b>	23 March 2010

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. MP Monsour Medical Practice Pty Ltd &lt;MP Monsour Medical Practice Superannuation Fund A/C&gt; 1,050,208 ordinary shares and 1,490,000 share options</li> <li>2. MPAMM Pty Ltd 4,134,074 ordinary shares and 1,614,000 share options</li> <li>3. Australian Technology Innovation Fund Limited 3,373,598 ordinary shares</li> <li>4. Australian Biofunds Investments Limited 199,553 ordinary shares</li> <li>5. Dr Michael Monsour &lt;Spyder Foundation A/C&gt; nil</li> </ol>
<b>Class</b>	Ordinary
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1. Dr Michael Monsour 38,187 ordinary shares</li> <li>2. MP Monsour Medical Practice Pty Ltd &lt;MP Monsour Medical Practice Superannuation Fund A/C&gt; 7,272 ordinary shares</li> <li>3. MPAMM Pty Ltd 173,516 ordinary shares</li> <li>4. Dr Michael Monsour &lt;Spyder Foundation A/C&gt; 337,843</li> </ol>
<b>Number disposed</b>	Australian Technology Innovation Fund Limited: 3,004,843 ordinary shares
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	38 cents per share based on closing share price 23 March 2010.
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. Dr Michael Monsour 38,187 ordinary shares</li> <li>2. MP Monsour Medical Practice Pty Ltd &lt;MP Monsour Medical Practice Superannuation Fund A/C&gt; 1,057,480 ordinary shares and 1,490,000 share options</li> <li>3. MPAMM Pty Ltd 4,307,590 ordinary shares and 1,614,000 share options</li> <li>4. Australian Technology Innovation Fund Limited 368,755 ordinary shares</li> <li>5. Australian Biofunds Investments Limited 199,755 ordinary shares</li> <li>6. Dr Michael Monsour &lt;Spyder Foundation A/C&gt; 337,843</li> </ol>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Shares acquired Dr Michael Monsour and associated entities were part of an in-specie distribution conducted by Australian Technology Innovation Fund Limited.</p>
---	--

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

+ See chapter 19 for defined terms.

For personal use only